Annual summary
Publications (original articles or review articles) published in 2012 from OUS - Department of Gynaecological Oncology
33 publications found
Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
Int J Radiat Oncol Biol Phys, 82 (3), e485-92
PubMed 22014954
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
BMC Cancer, 12, 454
PubMed 23039163
Nucleoside transporters are widely expressed in ovarian carcinoma effusions
Cancer Chemother Pharmacol, 69 (2), 467-75
PubMed 21822668
SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
Hum Pathol, 43 (5), 669-74
PubMed 21855113
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
Hum Pathol, 43 (4), 496-505
PubMed 21855111
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Virchows Arch, 460 (2), 193-202
PubMed 22249560
"The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
Qual Life Res, 21 (8), 1459-70
PubMed 22045155
Epithelial-mesenchymal transition in ovarian carcinoma
Front Oncol, 2, 33
PubMed 22655269
ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival
PLoS One, 7 (9), e46317
PubMed 23029477
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
Acta Obstet Gynecol Scand, 91 (3), 308-17
PubMed 22050605
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
Hum Pathol, 43 (4), 529-35
PubMed 21864883
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Clin Cancer Res, 18 (11), 3197-206
PubMed 22492981
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
Cancer Res, 72 (20), 5285-95
PubMed 22890239
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
PubMed 22476403
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
PubMed 22302409
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
PubMed 22652154
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
PubMed 22531637
Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization
Mol Oncol, 6 (1), 98-107
PubMed 22062770
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
Cancer, 118 (6), 1543-53
PubMed 22009736
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
PLoS One, 7 (4), e36263
PubMed 22558411
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells
BMC Cancer, 12, 201
PubMed 22642602
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Ann Oncol, 23 (10), 2613-9
PubMed 22539562
The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer
Anal Cell Pathol (Amst), 35 (4), 305-14
PubMed 22596183
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
Ann Oncol, 23 (5), 1178-84
PubMed 21965471
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
Virchows Arch, 461 (3), 291-8
PubMed 22824999
Photodynamic therapy of cervical intraepithelial neoplasia 1-3 and human papilloma virus (HMV) infection with methylaminolevulinate and hexaminolevulinate--a double-blind, dose-finding study
Lasers Surg Med, 44 (6), 468-74
PubMed 22693121
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
Ann Surg Oncol, 19 (2), 597-604
PubMed 21732142
Diagnosis and treatment of sarcoma of the uterus. A review
Acta Oncol, 51 (6), 694-705
PubMed 22793037
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
Eur J Cancer, 48 (14), 2146-54
PubMed 22382201
Borderline ovarian tumours
Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
PubMed 22321906
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
Hum Pathol, 43 (11), 2062-9
PubMed 22647351
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
Br J Cancer, 107 (4), 588-91
PubMed 22836511
Hyaluronan Synthase and Hyaluronidase Expression in Serous Ovarian Carcinoma is Related to Anatomic Site and Chemotherapy Exposure
Int J Mol Sci, 13 (10), 12925-38
PubMed 23202930




Go back
Print this page
E-mail this page
